Treatment

REGN7257 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia that is Refractory to or Relapsed on Immunosuppressive Therapy
This study is testing a new medicine called REGN7257 for severe aplastic anaemia (SAA). It's for people whose SAA hasn't improved with other treatments. Researchers want to see if the new medicine is safe and if it helps people get better.
For: Severe aplastic anemia (SAA)
France